Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies

Capitalizing on their extraordinary specificity, monoclonal antibodies (mAbs) have become one of the most reengineered classes of biological molecules. A major goal in many of these engineering efforts is to add new functionality to the parental mAb, including the addition of cytotoxins and imaging...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 110; no. 43; pp. 17456 - 17461
Main Authors Donaldson, Joshua M., Zer, Cindy, Avery, Kendra N., Bzymek, Krzysztof P., Horne, David A., Williams, John C.
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 22.10.2013
NATIONAL ACADEMY OF SCIENCES
National Acad Sciences
National Academy of Sciences, Washington, DC (United States)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Capitalizing on their extraordinary specificity, monoclonal antibodies (mAbs) have become one of the most reengineered classes of biological molecules. A major goal in many of these engineering efforts is to add new functionality to the parental mAb, including the addition of cytotoxins and imaging agents for medical applications. Herein, we present a unique peptide-binding site within the central cavity of the fragment antigen binding framework region of the chimeric, anti-epidermal growth factor receptor mAb cetuximab. We demonstrate through diffraction methods, biophysical studies, and sequence analysis that this peptide, a meditope, has moderate affinity for the Fab, is specific to cetuximab (i.e., does not bind to human IgGs), and has no significant effect on antigen binding. We further demonstrate by diffraction studies and biophysical methods that the meditope binding site can be grafted onto the anti-human epidermal growth factor receptor 2 mAb trastuzumab, and that the antigen binding affinity of the grafted trastuzumab is indistinguishable from the parental mAb. Finally, we demonstrate a bivalent meditope variant binds specifically and stably to antigen-bearing cells only in the presence of the meditope-enabled mAbs. Collectively, this finding and the subsequent characterization and engineering efforts indicate that this unique interface could serve as a noncovalent “linker” for any meditope-enabled mAb with applications in multiple mAb-based technologies including diagnostics, imaging, and therapeutic delivery.
Bibliography:http://dx.doi.org/10.1073/pnas.1307309110
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
SLAC-REPRINT-2014-168
USDOE Office of Science (SC)
AC02-76SF00515
Author contributions: J.M.D., C.Z., K.N.A., and J.C.W. designed research; J.M.D., C.Z., K.N.A., K.P.B., and J.C.W. performed research; J.M.D., C.Z., D.A.H., and J.C.W. contributed new reagents/analytic tools; J.M.D., C.Z., K.N.A., K.P.B., and J.C.W. analyzed data; and J.M.D., C.Z., K.N.A., K.P.B., and J.C.W. wrote the paper.
Edited* by Douglas C. Rees, Howard Hughes Medical Institute, California Institute of Technology, Pasadena, CA, and approved September 19, 2013 (received for review April 18, 2013)
1J.M.D. and C.Z. contributed equally to this work.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.1307309110